Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1789 to 1799 of 1799 entries
Sorted by: Best Match Show Resources per page
Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan.

Human vaccines & immunotherapeutics

Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, Tsuji M, Matsuda S, Fujino Y.
PMID: 34213406
Hum Vaccin Immunother. 2021 Nov 02;17(11):3975-3981. doi: 10.1080/21645515.2021.1947098. Epub 2021 Jul 02.

Many factors are related to vaccination intentions. However, gender differences in the determinants of intention to get the coronavirus disease 2019 (COVID-19) vaccine have not been fully investigated. This study examined gender differences in the determinants of willingness to...

Cite
Ishimaru T, Okawara M, Ando H, et al. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccin Immunother. 2021;17(11):3975-3981doi: 10.1080/21645515.2021.1947098.
Ishimaru, T., Okawara, M., Ando, H., Hino, A., Nagata, T., Tateishi, S., Tsuji, M., Matsuda, S., Fujino, Y. (2021). Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Human vaccines & immunotherapeutics, 17(11), 3975-3981. https://doi.org/10.1080/21645515.2021.1947098
Ishimaru, Tomohiro, et al. "Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan." Human vaccines & immunotherapeutics vol. 17,11 (2021): 3975-3981. doi: https://doi.org/10.1080/21645515.2021.1947098
Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, Tsuji M, Matsuda S, Fujino Y. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccin Immunother. 2021 Nov 02;17(11):3975-3981. doi: 10.1080/21645515.2021.1947098. Epub 2021 Jul 02. PMID: 34213406.
Copy Download .nbib Format: NLM
Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan.

Human vaccines & immunotherapeutics

Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, Tsuji M, Matsuda S, Fujino Y.
PMID: 34213406
Hum Vaccin Immunother. 2021 Nov 02;17(11):3975-3981. doi: 10.1080/21645515.2021.1947098. Epub 2021 Jul 02.

Many factors are related to vaccination intentions. However, gender differences in the determinants of intention to get the coronavirus disease 2019 (COVID-19) vaccine have not been fully investigated. This study examined gender differences in the determinants of willingness to...

Cite
Ishimaru T, Okawara M, Ando H, et al. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccin Immunother. 2021;17(11):3975-3981doi: 10.1080/21645515.2021.1947098.
Ishimaru, T., Okawara, M., Ando, H., Hino, A., Nagata, T., Tateishi, S., Tsuji, M., Matsuda, S., Fujino, Y. (2021). Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Human vaccines & immunotherapeutics, 17(11), 3975-3981. https://doi.org/10.1080/21645515.2021.1947098
Ishimaru, Tomohiro, et al. "Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan." Human vaccines & immunotherapeutics vol. 17,11 (2021): 3975-3981. doi: https://doi.org/10.1080/21645515.2021.1947098
Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, Tsuji M, Matsuda S, Fujino Y. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccin Immunother. 2021 Nov 02;17(11):3975-3981. doi: 10.1080/21645515.2021.1947098. Epub 2021 Jul 02. PMID: 34213406.
Copy Download .nbib Format: NLM
Changes in Presenteeism Six Months After Returning from Sick Leave Due to Mental Illness.

Journal of UOEH

Kusumoto A, Kajiki S, Anan T, Nagata T, Nagata M, Fujino Y, Mori K.
PMID: 34897167
J UOEH. 2021;43(4):385-395. doi: 10.7888/juoeh.43.385.

This study examines how psychological distress (measured by the K10 screening test) and presenteeism (measured by the quality and quantity method) change in the six months after returning to work from having taken a sick leave because of a...

Cite
Kusumoto A, Kajiki S, Anan T, et al. Changes in Presenteeism Six Months After Returning from Sick Leave Due to Mental Illness. J UOEH. 2021;43(4):385-395doi: 10.7888/juoeh.43.385.
Kusumoto, A., Kajiki, S., Anan, T., Nagata, T., Nagata, M., Fujino, Y., & Mori, K. (2021). Changes in Presenteeism Six Months After Returning from Sick Leave Due to Mental Illness. Journal of UOEH, 43(4), 385-395. https://doi.org/10.7888/juoeh.43.385
Kusumoto, Akira, et al. "Changes in Presenteeism Six Months After Returning from Sick Leave Due to Mental Illness." Journal of UOEH vol. 43,4 (2021): 385-395. doi: https://doi.org/10.7888/juoeh.43.385
Kusumoto A, Kajiki S, Anan T, Nagata T, Nagata M, Fujino Y, Mori K. Changes in Presenteeism Six Months After Returning from Sick Leave Due to Mental Illness. J UOEH. 2021;43(4):385-395. doi: 10.7888/juoeh.43.385. PMID: 34897167.
Copy Download .nbib Format: NLM
Highly rigid H3.1/H3.2-H3K9me3 domains set a barrier for cell fate reprogramming in trophoblast stem cells.

Genes & development

Hada M, Miura H, Tanigawa A, Matoba S, Inoue K, Ogonuki N, Hirose M, Watanabe N, Nakato R, Fujiki K, Hasegawa A, Sakashita A, Okae H, Miura K, Shikata D, Arima T, Shirahige K, Hiratani I, Ogura A.
PMID: 34992147
Genes Dev. 2022 Jan 06; doi: 10.1101/gad.348782.121. Epub 2022 Jan 06.

The placenta is a highly evolved, specialized organ in mammals. It differs from other organs in that it functions only for fetal maintenance during gestation. Therefore, there must be intrinsic mechanisms that guarantee its unique functions. To address this...

Cite
Hada M, Miura H, Tanigawa A, et al. Highly rigid H3.1/H3.2-H3K9me3 domains set a barrier for cell fate reprogramming in trophoblast stem cells. Genes Dev. 2022;doi: 10.1101/gad.348782.121.
Hada, M., Miura, H., Tanigawa, A., Matoba, S., Inoue, K., Ogonuki, N., Hirose, M., Watanabe, N., Nakato, R., Fujiki, K., Hasegawa, A., Sakashita, A., Okae, H., Miura, K., Shikata, D., Arima, T., Shirahige, K., Hiratani, I., & Ogura, A. (2022). Highly rigid H3.1/H3.2-H3K9me3 domains set a barrier for cell fate reprogramming in trophoblast stem cells. Genes & development, . https://doi.org/10.1101/gad.348782.121
Hada, Masashi, et al. "Highly rigid H3.1/H3.2-H3K9me3 domains set a barrier for cell fate reprogramming in trophoblast stem cells." Genes & development vol. (2022). doi: https://doi.org/10.1101/gad.348782.121
Hada M, Miura H, Tanigawa A, Matoba S, Inoue K, Ogonuki N, Hirose M, Watanabe N, Nakato R, Fujiki K, Hasegawa A, Sakashita A, Okae H, Miura K, Shikata D, Arima T, Shirahige K, Hiratani I, Ogura A. Highly rigid H3.1/H3.2-H3K9me3 domains set a barrier for cell fate reprogramming in trophoblast stem cells. Genes Dev. 2022 Jan 06; doi: 10.1101/gad.348782.121. Epub 2022 Jan 06. PMID: 34992147.
Copy Download .nbib Format: NLM
Preparation of Oxysterols by C-H Oxidation of Dibromocholestane with Ru(Bpga) Catalyst.

Molecules (Basel, Switzerland)

Fujii Y, Yoritate M, Makino K, Igawa K, Takeda D, Doiuchi D, Tomooka K, Uchida T, Hirai G.
PMID: 35011456
Molecules. 2021 Dec 30;27(1). doi: 10.3390/molecules27010225.

Seven mono- and dihydroxycholesterols were prepared by direct C-H oxidation of the cholestane skeleton with a recently developed Ru(Bpga) catalyst (Ru(Bpga) = [RuCl (bpga) (PPh

Cite
Fujii Y, Yoritate M, Makino K, et al. Preparation of Oxysterols by C-H Oxidation of Dibromocholestane with Ru(Bpga) Catalyst. Molecules. 2021;27(1)doi: 10.3390/molecules27010225.
Fujii, Y., Yoritate, M., Makino, K., Igawa, K., Takeda, D., Doiuchi, D., Tomooka, K., Uchida, T., & Hirai, G. (2021). Preparation of Oxysterols by C-H Oxidation of Dibromocholestane with Ru(Bpga) Catalyst. Molecules (Basel, Switzerland), 27(1), . https://doi.org/10.3390/molecules27010225
Fujii, Yui, et al. "Preparation of Oxysterols by C-H Oxidation of Dibromocholestane with Ru(Bpga) Catalyst." Molecules (Basel, Switzerland) vol. 27,1 (2021). doi: https://doi.org/10.3390/molecules27010225
Fujii Y, Yoritate M, Makino K, Igawa K, Takeda D, Doiuchi D, Tomooka K, Uchida T, Hirai G. Preparation of Oxysterols by C-H Oxidation of Dibromocholestane with Ru(Bpga) Catalyst. Molecules. 2021 Dec 30;27(1). doi: 10.3390/molecules27010225. PMID: 35011456; PMCID: PMC8746986.
Copy Download .nbib Format: NLM
Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.

Cancers

Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H, Takahashi N.
PMID: 34885012
Cancers (Basel). 2021 Nov 24;13(23). doi: 10.3390/cancers13235904.

Treatment-free remission (TFR) has become a therapeutic goal in chronic myeloid leukemia (CML), and approximately half of the patients with chronic phase-CML (CML-CP) with deep molecular remission (DMR) by tyrosine-kinase inhibitors (TKIs) have achieved TFR. However, the mechanism of...

Cite
Fujioka Y, Sugiyama D, Matsumura I, et al. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13235904.
Fujioka, Y., Sugiyama, D., Matsumura, I., Minami, Y., Miura, M., Atsuta, Y., Ohtake, S., Kiyoi, H., Miyazaki, Y., Nishikawa, H., & Takahashi, N. (2021). Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers, 13(23), . https://doi.org/10.3390/cancers13235904
Fujioka, Yuki, et al. "Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13235904
Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H, Takahashi N. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 24;13(23). doi: 10.3390/cancers13235904. PMID: 34885012; PMCID: PMC8657169.
Copy Download .nbib Format: NLM
Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan.

Thoracic cancer

Shiraishi T, Oda K, Yamasaki K, Kido T, Sennari K, Mukae H, Ohtani M, Fujino Y, Matsuda S, Fushimi K, Yatera K.
PMID: 34865321
Thorac Cancer. 2022 Jan;13(2):236-246. doi: 10.1111/1759-7714.14254. Epub 2021 Dec 05.

BACKGROUND: The safety profile of systemic chemotherapy for lung cancer patients with interstitial pneumonia (IP) in clinical practice remains unclear. Using Diagnostic Procedure Combination (DPC) data from the Japanese administrative database, we investigated the mortality of hospitalized lung cancer...

Cite
Shiraishi T, Oda K, Yamasaki K, et al. Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan. Thorac Cancer. 2021;13(2):236-246doi: 10.1111/1759-7714.14254.
Shiraishi, T., Oda, K., Yamasaki, K., Kido, T., Sennari, K., Mukae, H., Ohtani, M., Fujino, Y., Matsuda, S., Fushimi, K., & Yatera, K. (2022). Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan. Thoracic cancer, 13(2), 236-246. https://doi.org/10.1111/1759-7714.14254
Shiraishi, Tomoko, et al. "Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan." Thoracic cancer vol. 13,2 (2022): 236-246. doi: https://doi.org/10.1111/1759-7714.14254
Shiraishi T, Oda K, Yamasaki K, Kido T, Sennari K, Mukae H, Ohtani M, Fujino Y, Matsuda S, Fushimi K, Yatera K. Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan. Thorac Cancer. 2022 Jan;13(2):236-246. doi: 10.1111/1759-7714.14254. Epub 2021 Dec 05. PMID: 34865321.
Copy Download .nbib Format: NLM
A case of hypertensive disorders of pregnancy that developed at 9 weeks of gestation.

CEN case reports

Hayashi S, Ohashi N, Goto D, Isomura N, Isobe S, Fujikura T, Fujigaki Y, Shimizu A, Ito H, Yasuda H.
PMID: 33721266
CEN Case Rep. 2021 Nov;10(4):476-482. doi: 10.1007/s13730-021-00592-z. Epub 2021 Mar 15.

Preeclampsia and superimposed preeclampsia usually develop after 20 weeks of gestation. We report a case of a 35-year-old Japanese woman who developed hypertensive disorders of pregnancy (HDP) before 20 weeks of gestation. She presented with hypertension and proteinuria at...

Cite
Hayashi S, Ohashi N, Goto D, et al. A case of hypertensive disorders of pregnancy that developed at 9 weeks of gestation. CEN Case Rep. 2021;10(4):476-482doi: 10.1007/s13730-021-00592-z.
Hayashi, S., Ohashi, N., Goto, D., Isomura, N., Isobe, S., Fujikura, T., Fujigaki, Y., Shimizu, A., Ito, H., & Yasuda, H. (2021). A case of hypertensive disorders of pregnancy that developed at 9 weeks of gestation. CEN case reports, 10(4), 476-482. https://doi.org/10.1007/s13730-021-00592-z
Hayashi, Saki, et al. "A case of hypertensive disorders of pregnancy that developed at 9 weeks of gestation." CEN case reports vol. 10,4 (2021): 476-482. doi: https://doi.org/10.1007/s13730-021-00592-z
Hayashi S, Ohashi N, Goto D, Isomura N, Isobe S, Fujikura T, Fujigaki Y, Shimizu A, Ito H, Yasuda H. A case of hypertensive disorders of pregnancy that developed at 9 weeks of gestation. CEN Case Rep. 2021 Nov;10(4):476-482. doi: 10.1007/s13730-021-00592-z. Epub 2021 Mar 15. PMID: 33721266; PMCID: PMC8494829.
Copy Download .nbib Format: NLM
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.

Journal of neuro-oncology

Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M.
PMID: 34322829
J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28.

PURPOSE: Although we have shown the clinical benefit of bevacizumab (BEV) in the treatment of unresectable newly diagnosed glioblastomas (nd-GBM), the relationship between early radiographic response and survival outcome remains unclear. We performed a volumetric study of early radiographic...

Cite
Takigawa K, Hata N, Michiwaki Y, et al. Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. J Neurooncol. 2021;154(2):187-196doi: 10.1007/s11060-021-03812-9.
Takigawa, K., Hata, N., Michiwaki, Y., Hiwatashi, A., Yonezawa, H., Kuga, D., Hatae, R., Sangatsuda, Y., Fujioka, Y., Funakoshi, Y., Otsuji, R., Sako, A., Togao, O., Yoshiura, T., Yoshimoto, K., & Mizoguchi, M. (2021). Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. Journal of neuro-oncology, 154(2), 187-196. https://doi.org/10.1007/s11060-021-03812-9
Takigawa, Kosuke, et al. "Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma." Journal of neuro-oncology vol. 154,2 (2021): 187-196. doi: https://doi.org/10.1007/s11060-021-03812-9
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M. Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28. PMID: 34322829; PMCID: PMC8437873.
Copy Download .nbib Format: NLM
Risk Factors for Failure of Endoscopic Management of Stone-related Ureteral Strictures.

Urology journal

Sugino T, Taguchi K, Hamamoto S, Okada T, Isogai M, Tanaka Y, Unno R, Fujii Y, Hamakawa T, Ando R, Okada A, Yasui T.
PMID: 34431077
Urol J. 2021 Aug 25;6697. doi: 10.22037/uj.v18i.6697. Epub 2021 Aug 25.

PURPOSE: To investigate factors determining the outcomes of endoscopic management for stone-related ureteral stricture.MATERIALS AND METHODS: Data of patients who underwent endoscopic surgery for ureteral stricture due to stones from January 2016 to April 2020 were retrospectively analyzed. We...

Cite
Sugino T, Taguchi K, Hamamoto S, et al. Risk Factors for Failure of Endoscopic Management of Stone-related Ureteral Strictures. Urol J. 2021;6697doi: 10.22037/uj.v18i.6697.
Sugino, T., Taguchi, K., Hamamoto, S., Okada, T., Isogai, M., Tanaka, Y., Unno, R., Fujii, Y., Hamakawa, T., Ando, R., Okada, A., & Yasui, T. (2021). Risk Factors for Failure of Endoscopic Management of Stone-related Ureteral Strictures. Urology journal, 6697. https://doi.org/10.22037/uj.v18i.6697
Sugino, Teruaki, et al. "Risk Factors for Failure of Endoscopic Management of Stone-related Ureteral Strictures." Urology journal vol. (2021): 6697. doi: https://doi.org/10.22037/uj.v18i.6697
Sugino T, Taguchi K, Hamamoto S, Okada T, Isogai M, Tanaka Y, Unno R, Fujii Y, Hamakawa T, Ando R, Okada A, Yasui T. Risk Factors for Failure of Endoscopic Management of Stone-related Ureteral Strictures. Urol J. 2021 Aug 25;6697. doi: 10.22037/uj.v18i.6697. Epub 2021 Aug 25. PMID: 34431077.
Copy Download .nbib Format: NLM
FBP17-mediated finger-like membrane protrusions in cell competition between normal and RasV12-transformed cells.

iScience

Kamasaki T, Miyazaki Y, Ishikawa S, Hoshiba K, Kuromiya K, Tanimura N, Mori Y, Tsutsumi M, Nemoto T, Uehara R, Suetsugu S, Itoh T, Fujita Y.
PMID: 34485872
iScience. 2021 Aug 18;24(9):102994. doi: 10.1016/j.isci.2021.102994. eCollection 2021 Sep 24.

At the initial stage of carcinogenesis, cell competition often occurs between newly emerging transformed cells and the neighboring normal cells, leading to the elimination of transformed cells from the epithelial layer. For instance, when RasV12-transformed cells are surrounded by...

Cite
Kamasaki T, Miyazaki Y, Ishikawa S, et al. FBP17-mediated finger-like membrane protrusions in cell competition between normal and RasV12-transformed cells. iScience. 2021;24(9):102994doi: 10.1016/j.isci.2021.102994.
Kamasaki, T., Miyazaki, Y., Ishikawa, S., Hoshiba, K., Kuromiya, K., Tanimura, N., Mori, Y., Tsutsumi, M., Nemoto, T., Uehara, R., Suetsugu, S., Itoh, T., & Fujita, Y. (2021). FBP17-mediated finger-like membrane protrusions in cell competition between normal and RasV12-transformed cells. iScience, 24(9), 102994. https://doi.org/10.1016/j.isci.2021.102994
Kamasaki, Tomoko, et al. "FBP17-mediated finger-like membrane protrusions in cell competition between normal and RasV12-transformed cells." iScience vol. 24,9 (2021): 102994. doi: https://doi.org/10.1016/j.isci.2021.102994
Kamasaki T, Miyazaki Y, Ishikawa S, Hoshiba K, Kuromiya K, Tanimura N, Mori Y, Tsutsumi M, Nemoto T, Uehara R, Suetsugu S, Itoh T, Fujita Y. FBP17-mediated finger-like membrane protrusions in cell competition between normal and RasV12-transformed cells. iScience. 2021 Aug 18;24(9):102994. doi: 10.1016/j.isci.2021.102994. eCollection 2021 Sep 24. PMID: 34485872; PMCID: PMC8405961.
Copy Download .nbib Format: NLM
Showing 1789 to 1799 of 1799 entries